CA
MLTX icon

Clearstead Advisors’s MoonLake Immunotherapeutics MLTX Stock Holding History

Clearstead Advisors’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$780 Buy
+40
New +$725 ﹤0.01% 2782
2025
Q3 		– Sell
-490
Closed -$23.1K – 3184
2025
Q2 		$23.1K Buy
+490
New +$20K ﹤0.01% 1567

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Clearstead Advisors's MLTX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in MoonLake Immunotherapeutics (MLTX) in Q2 2026: 40 shares worth $780. The stake represents ﹤0.01% of the portfolio and ranks #2782 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in MLTX as recently as Q2 2025.

Clearstead Advisors first reported a position in MLTX in Q2 2025 and has held it in 2 quarters since. The position peaked at $23.1K in Q2 2025. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Clearstead Advisors held 40 shares of MoonLake Immunotherapeutics worth $780 as of Q2 2026.
  • MoonLake Immunotherapeutics was a new Clearstead Advisors position in Q2 2026.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2782 holding.
  • Clearstead Advisors first reported a position in MoonLake Immunotherapeutics in Q2 2025 and has held it in 2 quarters since.
  • Clearstead Advisors's MoonLake Immunotherapeutics position peaked at $23.1K in Q2 2025.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.